US Pharma MarketingASCO26: In vivo oncology approaches continue to show promise
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026. Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise. In vivo CAR T therapies are starting to show promise in data released at ASCO 2026. Credit: Nemes Laszlo / Shutterstock.com As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting through the mountain of data presented at the conference. Among that is data on novel cell therapy approaches, including in vivo cell…
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.
Source: Pharmaceutical Technology